Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

An open label, adaptive, phase 1 trial of high-dose oral nitazoxanide in healthy volunteers: an antiviral candidate for SARS-CoV-2

Lauren E Walker, Richard FitzGerald, Geoffrey Saunders, Rebecca Lyon, Michael Fisher, Karen Martin, Izabela Eberhart, Christie Woods, Sean Ewings, Colin Hale, View ORCID ProfileRajith KR Rajoli, Laura Else, Sujan Dilly-Penchala, Alieu Amara, David G Lalloo, Michael Jacobs, Henry Pertinez, Parys Hatchard, Robert Waugh, Megan Lawrence, Lucy Johnson, Keira Fines, Helen Reynolds, Timothy Rowland, Rebecca Crook, Kelly Byrne, Pavel Mozgunov, Thomas Jaki, View ORCID ProfileSaye Khoo, Andrew Owen, View ORCID ProfileGareth Griffiths, Thomas E Fletcher on behalf of the AGILE platform
doi: https://doi.org/10.1101/2021.09.10.21263376
Lauren E Walker
1University of Liverpool
2Liverpool University Hospitals NHS Foundation Trust
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Lauren.walker@liverpool.ac.uk
Richard FitzGerald
2Liverpool University Hospitals NHS Foundation Trust
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Geoffrey Saunders
3Southampton Clinical Trials Unit, University of Southampton, Southampton UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rebecca Lyon
2Liverpool University Hospitals NHS Foundation Trust
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Fisher
1University of Liverpool
2Liverpool University Hospitals NHS Foundation Trust
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karen Martin
3Southampton Clinical Trials Unit, University of Southampton, Southampton UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Izabela Eberhart
3Southampton Clinical Trials Unit, University of Southampton, Southampton UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christie Woods
2Liverpool University Hospitals NHS Foundation Trust
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sean Ewings
3Southampton Clinical Trials Unit, University of Southampton, Southampton UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Colin Hale
2Liverpool University Hospitals NHS Foundation Trust
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rajith KR Rajoli
1University of Liverpool
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rajith KR Rajoli
Laura Else
1University of Liverpool
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sujan Dilly-Penchala
1University of Liverpool
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alieu Amara
1University of Liverpool
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David G Lalloo
4Liverpool School of Tropical Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Jacobs
4Liverpool School of Tropical Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Henry Pertinez
1University of Liverpool
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Parys Hatchard
3Southampton Clinical Trials Unit, University of Southampton, Southampton UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Waugh
3Southampton Clinical Trials Unit, University of Southampton, Southampton UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Megan Lawrence
3Southampton Clinical Trials Unit, University of Southampton, Southampton UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lucy Johnson
3Southampton Clinical Trials Unit, University of Southampton, Southampton UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Keira Fines
3Southampton Clinical Trials Unit, University of Southampton, Southampton UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Helen Reynolds
1University of Liverpool
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Timothy Rowland
2Liverpool University Hospitals NHS Foundation Trust
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rebecca Crook
2Liverpool University Hospitals NHS Foundation Trust
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kelly Byrne
4Liverpool School of Tropical Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pavel Mozgunov
5MRC Biostatistics Unit, University of Cambridge
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Jaki
5MRC Biostatistics Unit, University of Cambridge
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Saye Khoo
1University of Liverpool
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Saye Khoo
Andrew Owen
1University of Liverpool
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gareth Griffiths
3Southampton Clinical Trials Unit, University of Southampton, Southampton UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Gareth Griffiths
Thomas E Fletcher
2Liverpool University Hospitals NHS Foundation Trust
4Liverpool School of Tropical Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Repurposing approved drugs may rapidly establish effective interventions during a public health crisis. This has yielded immunomodulatory treatments for severe COVID-19, but repurposed antivirals have not been successful to date because of redundancy of the target in vivo or suboptimal exposures at studied doses. Nitazoxanide is an FDA approved antiparasitic medicine, that physiologically-based pharmacokinetic (PBPK) modelling has indicated may provide antiviral concentrations across the dosing interval, when repurposed at higher than approved doses. Within the AGILE trial platform (NCT04746183) an open label, adaptive, phase 1 trial in healthy adult participants was undertaken with high dose nitazoxanide. Participants received 1500mg nitazoxanide orally twice-daily with food for 7 days. Primary outcomes were safety, tolerability, optimum dose and schedule. Intensive pharmacokinetic sampling was undertaken day 1 and 5 with Cmin sampling on day 3 and 7. Fourteen healthy participants were enrolled between 18th February and 11th May 2021. All 14 doses were completed by 10/14 participants. Nitazoxanide was safe and well tolerated with no significant adverse events. Moderate gastrointestinal disturbance (loose stools) occurred in 8 participants (57.1%), with urine and sclera discolouration in 12 (85.7%) and 9 (64.3%) participants, respectively, without clinically significant bilirubin elevation. This was self-limiting and resolved upon drug discontinuation. PBPK predictions were confirmed on day 1 but with underprediction at day 5. Median Cmin was above the in vitro target concentration on first dose and maintained throughout. Nitazoxanide administered at 1500mg BID with food was safe and well tolerated and a phase 1b/2a study is now being initiated in COVID-19 patients.

Competing Interest Statement

AO is Director of Tandem Nano Ltd. AO has received research funding from ViiV, Merck, Janssen and consultancy from Gilead, ViiV and Merck not related to the current paper. Ridgeback and GlaxoSmithKline have provided funding to the AGILE phase I/II platform to evaluate SARS-CoV-2 candidates independently of the current trial. GG has received funding from Janssen-Cilag, Astra Zeneca, Novartis, Astex, Roche, Heartflow, Celldex, BMS, BionTech, Cancer Research UK, NIHR, British Lung Foundation, Unitaid, GSK for unrelated academic clinical trials and programme funding. SK has received funding from Merck, ViiV, Janssen, Gilead for unrelated academic trials. No other conflicts are declared by the authors.

Clinical Trial

NCT04746183

Funding Statement

This trial was funded by Unitaid as part of a supplement to project LONGEVITY in response to the SARS-CoV-2 pandemic. AO also acknowledges research funding from EPSRC (EP/R024804/1; EP/S012265/1), NIH (R01AI134091; R24AI118397), European Commission (761104). The authors also acknowledge funding from Wellcome Trust [221590/Z/20/Z] and Medical Research Council [MR/V028391/1] for the AGILE phase I/II platform trial.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study protocol was reviewed and approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and West Midlands Edgbaston Research Ethics Committee. The study was coordinated by the National Institute for Health Research (NIHR) Southampton Clinical Trials Unit with participants recruited into the NIHR Royal Liverpool and Broadgreen Clinical Research Facility (UK).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Conflicts of interest statement AO is Director of Tandem Nano Ltd. AO has received research funding from ViiV, Merck, Janssen and consultancy from Gilead, ViiV and Merck not related to the current paper. Ridgeback and GlaxoSmithKline have provided funding to the AGILE phase I/II platform to evaluate SARS-CoV-2 candidates independently of the current trial. GG has received funding from Janssen-Cilag, Astra Zeneca, Novartis, Astex, Roche, Heartflow, Celldex, BMS, BionTech, Cancer Research UK, NIHR, British Lung Foundation, Unitaid, GSK for unrelated academic clinical trials and programme funding. SK has received funding from Merck, ViiV, Janssen, Gilead for unrelated academic trials. No other conflicts are declared by the authors.

  • Funding This trial was funded by Unitaid as part of a supplement to project LONGEVITY in response to the SARS-CoV-2 pandemic. AO also acknowledges research funding from EPSRC (EP/R024804/1; EP/S012265/1), NIH (R01AI134091; R24AI118397), European Commission (761104). The authors also acknowledge funding from Wellcome Trust [221590/Z/20/Z] and Medical Research Council [MR/V028391/1] for the AGILE phase I/II platform trial.

Data Availability

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to restrictions containing information that could compromise the privacy of research participants

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted September 11, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
An open label, adaptive, phase 1 trial of high-dose oral nitazoxanide in healthy volunteers: an antiviral candidate for SARS-CoV-2
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
An open label, adaptive, phase 1 trial of high-dose oral nitazoxanide in healthy volunteers: an antiviral candidate for SARS-CoV-2
Lauren E Walker, Richard FitzGerald, Geoffrey Saunders, Rebecca Lyon, Michael Fisher, Karen Martin, Izabela Eberhart, Christie Woods, Sean Ewings, Colin Hale, Rajith KR Rajoli, Laura Else, Sujan Dilly-Penchala, Alieu Amara, David G Lalloo, Michael Jacobs, Henry Pertinez, Parys Hatchard, Robert Waugh, Megan Lawrence, Lucy Johnson, Keira Fines, Helen Reynolds, Timothy Rowland, Rebecca Crook, Kelly Byrne, Pavel Mozgunov, Thomas Jaki, Saye Khoo, Andrew Owen, Gareth Griffiths, Thomas E Fletcher
medRxiv 2021.09.10.21263376; doi: https://doi.org/10.1101/2021.09.10.21263376
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
An open label, adaptive, phase 1 trial of high-dose oral nitazoxanide in healthy volunteers: an antiviral candidate for SARS-CoV-2
Lauren E Walker, Richard FitzGerald, Geoffrey Saunders, Rebecca Lyon, Michael Fisher, Karen Martin, Izabela Eberhart, Christie Woods, Sean Ewings, Colin Hale, Rajith KR Rajoli, Laura Else, Sujan Dilly-Penchala, Alieu Amara, David G Lalloo, Michael Jacobs, Henry Pertinez, Parys Hatchard, Robert Waugh, Megan Lawrence, Lucy Johnson, Keira Fines, Helen Reynolds, Timothy Rowland, Rebecca Crook, Kelly Byrne, Pavel Mozgunov, Thomas Jaki, Saye Khoo, Andrew Owen, Gareth Griffiths, Thomas E Fletcher
medRxiv 2021.09.10.21263376; doi: https://doi.org/10.1101/2021.09.10.21263376

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Pharmacology and Therapeutics
Subject Areas
All Articles
  • Addiction Medicine (240)
  • Allergy and Immunology (521)
  • Anesthesia (125)
  • Cardiovascular Medicine (1422)
  • Dentistry and Oral Medicine (217)
  • Dermatology (158)
  • Emergency Medicine (291)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (584)
  • Epidemiology (10303)
  • Forensic Medicine (6)
  • Gastroenterology (527)
  • Genetic and Genomic Medicine (2631)
  • Geriatric Medicine (254)
  • Health Economics (497)
  • Health Informatics (1736)
  • Health Policy (790)
  • Health Systems and Quality Improvement (674)
  • Hematology (267)
  • HIV/AIDS (566)
  • Infectious Diseases (except HIV/AIDS) (12098)
  • Intensive Care and Critical Care Medicine (649)
  • Medical Education (273)
  • Medical Ethics (83)
  • Nephrology (289)
  • Neurology (2463)
  • Nursing (145)
  • Nutrition (378)
  • Obstetrics and Gynecology (493)
  • Occupational and Environmental Health (568)
  • Oncology (1324)
  • Ophthalmology (402)
  • Orthopedics (147)
  • Otolaryngology (237)
  • Pain Medicine (168)
  • Palliative Medicine (51)
  • Pathology (343)
  • Pediatrics (782)
  • Pharmacology and Therapeutics (330)
  • Primary Care Research (296)
  • Psychiatry and Clinical Psychology (2402)
  • Public and Global Health (5013)
  • Radiology and Imaging (894)
  • Rehabilitation Medicine and Physical Therapy (529)
  • Respiratory Medicine (682)
  • Rheumatology (309)
  • Sexual and Reproductive Health (256)
  • Sports Medicine (245)
  • Surgery (298)
  • Toxicology (45)
  • Transplantation (141)
  • Urology (108)